What it is
Epithalon, also written Epitalon, is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine (AEDG). It was developed by Vladimir Khavinson’s group at the St. Petersburg Institute of Bioregulation and Gerontology as a defined synthetic successor to Epithalamin — a crude polypeptide extract of bovine pineal gland the same group had studied since the 1970s.
The proposed mechanism has two parts. The first is pineal: Epithalon is described as restoring age-related decline in melatonin rhythm. The second is genomic: short peptides of this class are proposed to interact with regulatory regions of DNA and alter gene expression, including hTERT — the catalytic subunit of telomerase, the enzyme that maintains the protective caps at the ends of chromosomes.
That second claim is why Epithalon appears on longevity websites. It also deserves the most scrutiny, so most of this page is spent on it.
What the research shows
Cell culture. The foundational finding is a 2003 paper in the Bulletin of Experimental Biology and Medicine reporting that Epithalon induced telomerase activity and telomere elongation in cultured human fetal fibroblasts — a cell-culture experiment, not a human outcome, and a Khavinson-group paper.
A 2025 study in Biogerontology revisited the question in human cell lines. In normal mammary epithelial cells, Epitalon upregulated hTERT and raised telomerase activity substantially. In cancer cell lines, hTERT rose but telomerase activity did not follow — instead those cells showed roughly a ten-fold increase in alternative lengthening of telomeres (ALT) activity. A more independent and granular dataset than existed before, and still entirely cell-based.
Animal work. Lifespan and tumor-incidence studies in flies, mice and rats have reported favorable results for both Epithalamin and Epithalon. The Alzheimer’s Drug Discovery Foundation’s independent Cognitive Vitality review states the problem directly: “none of these results has been replicated by a lab independent of Dr. Khavinson’s group.”
Human data. Two clinical studies are of consequence, and both used Epithalamin, the bovine pineal extract — not the synthetic tetrapeptide. One treated 266 older adults over two to three years; the paper is not available in English. The other was a placebo-controlled trial in roughly 70 adults around age 65, given intramuscular Epithalamin every six months for three years with follow-up to twelve years, reporting 28% lower mortality in the cardiovascular-disease subgroup. The ADDF review notes these results “have not been validated by an independent trial.”
That review’s summary judgment is worth quoting: “It is critical to note that every preclinical and clinical study discussed here has been conducted by Dr. Khavinson’s group in Russia with no independent confirmation.” It adds that at least half of roughly 110 published articles are in Russian with no English translation, and that there are no human studies of effects on cognition or neuroprotection.
FDA’s own assessment. Reviewing Epitalon in 2026, FDA scientists’ briefing document identified only one relevant human study — a small sublingual study measuring melatonin metabolites, not clinical outcomes. FDA noted the nonclinical work came from a single Russian group, used fixed doses without dose-response assessment, used female mice only, was not independently replicated, and ran carcinogenicity studies for about five and a half months rather than the standard two years.
Labeled accurately, this evidence is preliminary, largely preclinical, and largely from one group. Nothing here establishes that Epithalon extends human lifespan, slows aging, lengthens telomeres in living people, or improves cognition.
Who may be a candidate
Adults who raise Epithalon with us are usually:
- Interested in longevity medicine and wanting a physician’s honest appraisal of something they have read about
- Working through a comprehensive assessment of aging markers, inflammation and metabolic health
- Noticing age-related changes in sleep timing and wanting a circadian and hormonal evaluation
- Seeking to understand risk, not just potential benefit
A personal or family history of malignancy warrants particular caution and detailed discussion.
What treatment looks like here
Comprehensive evaluation. Longevity medicine done properly starts with measurement, not a peptide. Dr. St. Marie evaluates cardiometabolic risk, inflammatory burden, hormonal status, sleep, body composition, functional capacity and cancer screening status before discussing any experimental compound.
Laboratory work. Typically an advanced lipid and lipoprotein panel, hs-CRP, A1c and fasting insulin, comprehensive metabolic and hepatic panels, thyroid studies, full hormone evaluation, vitamin D, and age- and sex-appropriate cancer screening, tracked over time.
Candid discussion of regulatory status. Epitalon is not FDA-approved and its compounding position in the United States is unsettled and actively changing. Dr. St. Marie explains where the science and the regulation each stand before anything is prescribed, and anything used is prescribed and supervised by Dr. St. Marie through his licensed pharmacy relationships, after individual evaluation.
Monitoring. Anything we initiate is tracked against pre-defined labs and endpoints on a set schedule, with clear criteria for stopping.
What we don’t yet know
Almost everything that matters.
We do not know whether Epithalon does anything measurable in a living human being. The human data concerns a different preparation, from one group, without independent replication.
We do not know whether telomere lengthening — if it occurs in people — is desirable. Telomerase activity is a hallmark of most cancers. The 2025 finding that cancer cell lines respond differently than normal cells, engaging alternative lengthening pathways, is scientifically interesting and clinically unresolved. Not a reason for alarm, and not a reason for confidence.
We do not know its long-term human safety, because no long-term safety study exists; the available carcinogenicity work was short by conventional standards. We do not know the pharmacokinetics of subcutaneous administration, the route most commonly discussed, because it has not been studied. And we do not know how a compounded preparation would perform on purity, aggregation and immunogenicity — questions FDA raised explicitly and that remain unanswered.
No claim of safety can be made for this compound. Anti-aging and life extension are not established outcomes — they are hypotheses under study.
FDA & regulatory status
Epitalon is not approved by the FDA for any use.
It was placed in Category 2 of FDA’s interim 503A bulk drug substances policy on September 29, 2023 — the category for substances FDA determined raise significant safety risks in compounding. In April 2026 it was removed from Category 2 after its nomination was withdrawn and referred to the Pharmacy Compounding Advisory Committee.
At the July 23–24, 2026 meeting, FDA scientists recommended against adding Epitalon to the 503A Bulks List. The advisory committee voted narrowly in favor anyway.
That vote is not an approval and is not binding. FDA must still complete formal notice-and-comment rulemaking before Epitalon could lawfully be compounded — a process that may extend into 2027 or beyond. It also has no USP monograph and is not recognized in the European or Japanese pharmacopoeias.
Questions we get
Does Epithalon lengthen telomeres, and is it an anti-aging treatment? It has increased telomere length in cultured cells. Whether it does so in living humans has not been demonstrated, and telomere length remains a research marker, not a validated clinical endpoint. Anti-aging is not an established outcome — this is a compound being studied for effects related to aging biology, which is a materially different statement.
Why is the evidence weak if there are over a hundred papers? Volume is not independence. When one group produces nearly all of the literature, much of it untranslated, and no outside laboratory has reproduced the central findings, caution is the appropriate stance.
Could telomerase activation increase cancer risk? It is a legitimate theoretical concern that has not been resolved in humans. We would not consider this compound without a thorough oncologic history and current, age-appropriate cancer screening.
Can I get it at your Orlando office? Epitalon’s regulatory position in the United States is unsettled and actively changing. Dr. St. Marie will walk you through where it currently stands, and where it does and does not fit alongside the longevity measures that already have evidence behind them.
Related
- 11 — Elevate Health, Performance & Longevity, where this compound is almost always raised
- 1 — Comprehensive Health Assessment & Foundation, because longevity medicine starts with measurement
- 10 — Sleep, Recovery & Restoration, given the proposed pineal and melatonin effects
- 2 — Inflammation, Disease Risk & Prevention, which is where the durable longevity gains actually are
Next step
The most effective longevity medicine available today is unglamorous: controlling vascular risk, correcting metabolic dysfunction, restoring sleep, maintaining muscle, screening on schedule. We measure all of it, and we tell you honestly where experimental compounds do and do not fit.
Candidacy for any therapy discussed here is determined by Dr. St. Marie through comprehensive evaluation and lab work. It is not appropriate for everyone.
To schedule, call 407-506-4776 or request an appointment online.
Osteopathic Health of Orlando · 4625 Halder Lane, Suite C, Orlando, FL 32814